Geode Capital Management
ESLA icon

Geode Capital Management’s Estrella Immunopharma ESLA Stock Holding History

Geode Capital Management’s Portfolio ESLA Stock Details ESLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$147K Sell
141,321
-16,164
-10% -$21.1K ﹤0.01% 4012
2026
Q1 		$167K Buy
157,485
+47,677
+43% +$54.8K ﹤0.01% 3979
2025
Q4 		$171K Buy
109,808
+8,318
+8% +$15.7K ﹤0.01% 3962
2025
Q3 		$121K Sell
101,490
-1,847
-2% -$1.77K ﹤0.01% 4081
2025
Q2 		$88.5K Buy
103,337
+3,164
+3% +$3.07K ﹤0.01% 4094
2025
Q1 		$92.9K Buy
100,173
+6,755
+7% +$7.43K ﹤0.01% 4050
2024
Q4 		$106K Buy
93,418
+16,862
+22% +$17K ﹤0.01% 4084
2024
Q3 		$88.8K Buy
76,556
+18,342
+32% +$23.6K ﹤0.01% 4138
2024
Q2 		$61.1K Hold
58,214
– – ﹤0.01% 4240
2024
Q1 		$70.4K Buy
58,214
+1,999
+4% +$2.24K ﹤0.01% 4253
2023
Q4 		$63K Buy
+56,215
New +$85K ﹤0.01% 4298

Other funds holding ESLA

AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
US Bancorp
US Bancorp Minneapolis, Minnesota $91.6B AUM 29.2% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Geode Capital Management's ESLA Position: Q2 2026 in Review

Geode Capital Management reduced its Estrella Immunopharma (ESLA) stake by 10% in Q2 2026, selling an estimated $21.1K and leaving 141,321 shares worth $147K. The position accounts for ﹤0.01% of the portfolio, ranked #4012.

Geode Capital Management first reported a position in ESLA in Q4 2023 and has held it in 11 quarters since. The position peaked at $171K in Q4 2025. 15 funds tracked by Wall St. Rank hold ESLA as of Q2 2026.

  • Geode Capital Management held 141,321 shares of Estrella Immunopharma worth $147K as of Q2 2026.
  • Geode Capital Management sold 16,164 Estrella Immunopharma shares in Q2 2026, an estimated $21.1K.
  • Estrella Immunopharma made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #4012 holding.
  • Geode Capital Management first reported a position in Estrella Immunopharma in Q4 2023 and has held it in 11 quarters since.
  • Geode Capital Management's Estrella Immunopharma position peaked at $171K in Q4 2025.
  • 15 funds tracked by Wall St. Rank held Estrella Immunopharma as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.